Shield Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Shield Therapeutics şirketinin toplam hissedar öz sermayesi $541.0K ve toplam borcu $19.7M olup, bu da borç-öz sermaye oranını 3637.5% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $46.8M ve $46.2M dir.

Anahtar bilgiler

3,637.5%

Borç/özkaynak oranı

US$19.68m

Borç

Faiz karşılama oranın/a
NakitUS$8.10m
EşitlikUS$541.00k
Toplam yükümlülüklerUS$46.22m
Toplam varlıklarUS$46.76m

Son finansal sağlık güncellemeleri

Recent updates

Shield Therapeutics plc (LON:STX) Stock's 28% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Oct 30
Shield Therapeutics plc (LON:STX) Stock's 28% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Shield Therapeutics (LON:STX) Is Making Moderate Use Of Debt

Oct 12
Shield Therapeutics (LON:STX) Is Making Moderate Use Of Debt

Shield Therapeutics plc's (LON:STX) Shares Leap 44% Yet They're Still Not Telling The Full Story

Aug 01
Shield Therapeutics plc's (LON:STX) Shares Leap 44% Yet They're Still Not Telling The Full Story

Increases to Shield Therapeutics plc's (LON:STX) CEO Compensation Might Cool off for now

Jun 13
Increases to Shield Therapeutics plc's (LON:STX) CEO Compensation Might Cool off for now

Market Might Still Lack Some Conviction On Shield Therapeutics plc (LON:STX) Even After 35% Share Price Boost

May 22
Market Might Still Lack Some Conviction On Shield Therapeutics plc (LON:STX) Even After 35% Share Price Boost

Here's Why We're Watching Shield Therapeutics' (LON:STX) Cash Burn Situation

Mar 02
Here's Why We're Watching Shield Therapeutics' (LON:STX) Cash Burn Situation

What Does The Future Hold For Shield Therapeutics plc (LON:STX)? These Analysts Have Been Cutting Their Estimates

May 06
What Does The Future Hold For Shield Therapeutics plc (LON:STX)? These Analysts Have Been Cutting Their Estimates

Shield Therapeutics (LON:STX) Shareholders Have Enjoyed An Impressive 111% Share Price Gain

Mar 15
Shield Therapeutics (LON:STX) Shareholders Have Enjoyed An Impressive 111% Share Price Gain

We're Interested To See How Shield Therapeutics (LON:STX) Uses Its Cash Hoard To Grow

Jan 27
We're Interested To See How Shield Therapeutics (LON:STX) Uses Its Cash Hoard To Grow

Trade Alert: The CEO & Director Of Shield Therapeutics plc (LON:STX), Timothy Watts, Has Just Spent UK£70k Buying 22% More Shares

Dec 15
Trade Alert: The CEO & Director Of Shield Therapeutics plc (LON:STX), Timothy Watts, Has Just Spent UK£70k Buying 22% More Shares

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: STX 'nin kısa vadeli varlıkları ( $27.8M ) kısa vadeli yükümlülüklerini ( $26.5M ) aşıyor.

Uzun Vadeli Yükümlülükler: STX şirketinin kısa vadeli varlıkları ( $27.8M ) uzun vadeli yükümlülüklerini ( $19.7M ) aşmaktadır.


Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: STX 'nin net borç/öz sermaye oranı ( 2140.5% ) yüksek olarak değerlendiriliyor.

Borcun Azaltılması: STX şirketinin borç/öz sermaye oranı son 5 yılda 0% seviyesinden 3637.5% seviyesine yükseldi.


Bilanço


Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: STX şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: STX serbest nakit akışı her yıl % 32.1 1.1 yıl yetecek nakit akışına sahip olacaktır.


Sağlıklı şirketleri keşfedin